Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG099
MIFTS: 67

Lung Disease

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lung Disease

About this section

MalaCards integrated aliases for Lung Disease:

Name: Lung Disease 12 15
Lung Diseases 55 43 44 73
Disorder of Lung 29

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:850
ICD10 33 J98.4 J60-J70
MeSH 44 D008171
NCIt 50 C3198
SNOMED-CT 68 19829001
UMLS 73 C0024115
Sources

Summaries for Lung Disease

About this section
MedlinePlus : 43 When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Lung Disease, also known as lung diseases, is related to interstitial lung disease and pulmonary disease, chronic obstructive, and has symptoms including dyspnea, apnea and hemoptysis. An important gene associated with Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Metabolism of proteins and Toll-like Receptor Signaling Pathway. The drugs Pirfenidone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.

Sources

Related Diseases for Lung Disease

About this section

Diseases related to Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 584)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 34.1 ABCA3 CXCL8 IFIH1 IL10 IL1B ITGA3
2 pulmonary disease, chronic obstructive 33.1 CFTR CXCL8 ELANE SERPINA1 SFTPB SFTPD
3 desquamative interstitial pneumonia 32.7 ABCA3 MUC5B SFTPC
4 pneumoconiosis 32.7 CXCL8 IL1B MUC5B SERPINA1 TNF
5 alpha-1-antitrypsin deficiency 32.6 CXCL8 ELANE SERPINA1
6 cystic fibrosis 32.5 CFTR CXCL8 ELANE SERPINA1 SFTPD
7 extrinsic allergic alveolitis 32.5 CXCL8 IL10 IL1B SFTPD
8 surfactant dysfunction 32.5 ABCA3 SFTPA1 SFTPB SFTPC
9 silicosis 32.4 CXCL8 IL1B SFTPD TNF
10 bagassosis 32.3 CXCL8 IL1B
11 bronchopulmonary dysplasia 32.3 CXCL8 ELANE SFTPB
12 pulmonary fibrosis 32.3 IL1B MUC5B SFTPA1 SFTPA2 SFTPC SFTPD
13 pulmonary fibrosis, idiopathic 32.3 ABCA3 CXCL8 ELANE IL1B MUC5B SFTPA1
14 respiratory failure 32.2 CXCL8 ELANE SERPINA1 SFTPB SFTPC SFTPD
15 aspergillosis 32.2 CFTR ELANE IL10 SFTPA2 SFTPD TNF
16 bronchiolitis 32.2 CXCL8 IL10 MUC5B TNF
17 asthma 32.2 CFTR CXCL8 ELANE IL10 IL1B TNF
18 allergic bronchopulmonary aspergillosis 32.1 CFTR SFTPA2 SFTPD
19 pulmonary alveolar proteinosis 32.1 SFTPB SFTPC SFTPD
20 respiratory distress syndrome in premature infants 32.1 ABCA3 SFTPA1 SFTPB SFTPC
21 bronchiolitis obliterans 32.1 CXCL8 IL10 TNF
22 pneumonia 32.0 CXCL8 ELANE IL10 IL1B MUC5B SFTPB
23 idiopathic interstitial pneumonia 32.0 CXCL8 ELANE MUC5B SFTPA1 SFTPA2 SFTPC
24 arthritis 31.2 CXCL8 IL10 IL1B TNF
25 bronchiectasis 30.9 CFTR CXCL8 ELANE SERPINA1
26 mycobacterium abscessus 30.8 CFTR CXCL8 SERPINA1 TNF
27 bronchitis 30.6 CFTR CXCL8 ELANE SERPINA1 TNF
28 sleep apnea 30.4 CXCL8 IL1B TNF
29 haemophilus influenzae 30.3 CXCL8 IL1B TNF
30 chorioamnionitis 30.3 CXCL8 ELANE IL1B TNF
31 viral infectious disease 30.2 CXCL8 IFIH1 IL10 IL1B TNF
32 colitis 30.1 CXCL8 IL10 IL1B TNF
33 microscopic polyangiitis 30.1 IL10 TNF
34 pulmonary emphysema 30.1 ELANE SERPINA1 SFTPC SFTPD
35 bacterial pneumonia 30.1 CXCL8 ELANE SFTPB SFTPD
36 ulcerative colitis 30.0 CXCL8 IL10 IL1B TNF
37 acquired immunodeficiency syndrome 30.0 IL10 IL1B TNF
38 vasculitis 30.0 ELANE SERPINA1 TNF
39 psoriasis 30.0 CXCL8 IFIH1 IL10 IL1B TNF
40 rheumatic disease 29.9 IL10 IL1B TNF
41 pulmonary edema 29.9 CFTR CXCL8 IL10 IL1B TNF
42 cytomegalovirus infection 29.9 CXCL8 IL1B TNF
43 adult respiratory distress syndrome 29.9 CXCL8 ELANE IL10 SFTPB SFTPC TNF
44 acute respiratory distress syndrome 29.8 CXCL8 ELANE IL1B SFTPB SFTPC SFTPD
45 neonatal respiratory failure 29.8 ABCA3 SFTPB SFTPC
46 clonorchiasis 29.8 CXCL8 IL10 TNF
47 funisitis 29.8 CXCL8 IL10 IL1B
48 crohn's colitis 29.7 CXCL8 IL1B TNF
49 contact dermatitis 29.7 CXCL8 IL10 IL1B TNF
50 peritonitis 29.7 CXCL8 IL10 IL1B TNF

Graphical network of the top 20 diseases related to Lung Disease:



Diseases related to Lung Disease
Sources

Symptoms & Phenotypes for Lung Disease

About this section

UMLS symptoms related to Lung Disease:


dyspnea, apnea, hemoptysis, snoring, coughing, labored breathing

MGI Mouse Phenotypes related to Lung Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
2 hematopoietic system MP:0005397 10.07 CFTR ELANE IFIH1 IL10 IL1B MUC5B
3 immune system MP:0005387 10.03 CFTR ELANE IFIH1 IL10 IL1B ITGA3
4 mortality/aging MP:0010768 10.03 ABCA3 CFTR ELANE IFIH1 IL10 IL1B
5 neoplasm MP:0002006 9.56 ELANE IL10 IL1B ITGA3 SFTPC TERT
6 respiratory system MP:0005388 9.4 ABCA3 CFTR IL10 ITGA3 MUC5B SFTPA1
Sources

Drugs & Therapeutics for Lung Disease

About this section

Drugs for Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53179-13-8 40632
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
3 Beractant Approved Phase 4,Phase 2,Not Applicable 108778-82-1
4
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147536-97-8 104865
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83905-01-5 55185 447043
6
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
8
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
9
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 78919-13-8 6443959
10
Terbutaline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23031-25-6 5403
11
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
12
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
13
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
14 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
16
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
17
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
18
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
19
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-65-8 453 6251
20
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232
21
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72332-33-3 688561
22
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
23
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
24
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 98-96-4 1046
25
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54-85-3 3767
26
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
27
Metformin Approved Phase 4,Phase 2,Early Phase 1 657-24-9 14219 4091
28
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
29
Epoprostenol Approved Phase 4,Phase 3,Phase 2 61849-14-7, 35121-78-9 5280427 5282411
30
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
31
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
32
Dalteparin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 9005-49-6
33
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
34
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 1,Not Applicable 59467-70-8 4192
35
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
36
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113775-47-6 68602 5311068
37
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
38
Tazobactam Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 89786-04-9 123630
39
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
40
Salmon Calcitonin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 47931-85-1 16129616
41
Penicillin G Approved, Vet_approved Phase 4,Phase 3 61-33-6 5904
42
Piperacillin Approved Phase 4,Phase 2,Phase 3,Not Applicable 66258-76-2 43672
43
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
44
Cefuroxime Approved Phase 4,Phase 2,Phase 3,Not Applicable 55268-75-2 5361202 5479529
45
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
46
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
47
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
48
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
49
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100986-85-4 149096
50
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Prevention of Chronic Lung Disease (CLD) in Preterm Infants Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
3 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
4 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
5 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
6 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
7 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
8 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
9 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
10 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
11 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
12 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
13 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
14 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
15 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
16 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
17 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
18 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
19 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
20 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
21 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
22 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
23 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
24 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
25 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
26 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
27 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
28 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
29 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
30 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
31 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
32 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
33 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
34 Airway Effects of Tiotropium in Patients With COPD Unknown status NCT02683668 Phase 4
35 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
36 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
37 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
38 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
39 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
40 Preterm Infant Inhaled Albuterol Dosing Unknown status NCT02447250 Phase 4 Varied albuterol dose response
41 Bronchiolitis All-study, SE-Norway Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
42 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
43 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
44 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
45 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
46 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
47 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
48 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
49 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
50 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4

Search NIH Clinical Center for Lung Disease

Cochrane evidence based reviews: lung diseases

Sources

Genetic Tests for Lung Disease

About this section

Genetic tests related to Lung Disease:

# Genetic test Affiliating Genes
1 Disorder of Lung 29
Sources

Anatomical Context for Lung Disease

About this section

MalaCards organs/tissues related to Lung Disease:

41
Lung, Testes, Heart, Neutrophil, Bone, Bone Marrow, Brain
Sources

Publications for Lung Disease

About this section

Articles related to Lung Disease:

(show top 50) (show all 4903)
# Title Authors Year
1
Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. ( 30291871 )
2019
2
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. ( 30456167 )
2019
3
Coexistent sarcoidosis and lymphangioleiomyomatosis in a patient with cystic lung disease. ( 30519468 )
2019
4
Favorable outcome with early initiation of VV-ECMO for unilateral lung disease in children. ( 30555780 )
2019
5
Role of chest ultrasound in neonatal lung disease: a review of current evidences. ( 28870125 )
2019
6
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. ( 29936475 )
2018
7
Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. ( 29353024 )
2018
8
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. ( 29914454 )
2018
9
Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. ( 28379478 )
2018
10
Exertional Oxygen Requirements During Exercise Training in Advanced Interstitial Lung Disease. ( 29952810 )
2018
11
Renewed Promise of Non-ionizing Radiation Imaging for Chronic Lung Disease in Preterm Infants. ( 29944841 )
2018
12
Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. ( 29966637 )
2018
13
Galectin-3 Interacts with the CHI3L1 Axis and Contributes to Hermansky-Pudlak Syndrome Lung Disease. ( 29427412 )
2018
14
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. ( 29382380 )
2018
15
Screening for pulmonary hypertension in interstitial lung disease: Many reasons to ECHO! ( 29415370 )
2018
16
Right extrapleural completion pneumonectomy for fibrocavitary nontuberculous mycobacterial lung disease. ( 29445484 )
2018
17
Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. ( 29957284 )
2018
18
The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. ( 29977547 )
2018
19
Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box. ( 29957036 )
2018
20
Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. ( 29745875 )
2018
21
Lemierre's syndrome: cavitary lung disease caused by uncommon bacteria. ( 29669776 )
2018
22
Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease. ( 29936470 )
2018
23
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. ( 29376545 )
2018
24
Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy? ( 29382307 )
2018
25
Granulomatous-lymphocytic interstitial lung disease at the emergency department: Think about it! ( 29970784 )
2018
26
Smoking-Related Stigma Expressed by Physiotherapists toward Individuals with Lung Disease. ( 29434420 )
2018
27
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
28
The Four Corners Sign: A Specific Imaging Feature in Differentiating Systemic Sclerosis-related Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. ( 29346191 )
2018
29
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
30
Autoreactive T cells to citrullinated HSP90 are associated with interstitial lung disease in rheumatoid arthritis. ( 29968330 )
2018
31
Risk factors for primary SjAPgren syndrome-associated interstitial lung disease. ( 29850114 )
2018
32
Tackling injustices of occupational lung disease acquired in South African mines: recent developments and ongoing challenges. ( 29954399 )
2018
33
Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease. ( 29970696 )
2018
34
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. ( 29961690 )
2018
35
Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. ( 29580292 )
2018
36
Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. ( 29446698 )
2018
37
Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. ( 29607151 )
2018
38
Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary SjAPgren syndrome patients: A case-control study. ( 29901591 )
2018
39
SjAPgren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis. ( 29808154 )
2018
40
Bronchial wash culture is less valuable in patients suspected to have nontuberculous mycobacteria lung disease for bilateral bronchiectasis with nodules. ( 29900897 )
2018
41
Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. ( 29422324 )
2018
42
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
43
Measures that matter: Health-related quality of life in children with interstitial lung disease. ( 29943900 )
2018
44
Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. ( 29301535 )
2018
45
Mica pneumoconiosis: a neglected occupational lung disease. ( 29759917 )
2018
46
Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). ( 29414453 )
2018
47
Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. ( 29430176 )
2018
48
International management platform for children's interstitial lung disease (chILD-EU). ( 29056600 )
2018
49
Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey. ( 29429447 )
2018
50
Hepatopulmonary Syndrome and Diffuse Interstitial Lung Disease: An Unusual Combination. ( 29588084 )
2018
Sources

Variations for Lung Disease

About this section
Sources

Expression for Lung Disease

About this section
Search GEO for disease gene expression data for Lung Disease.
Sources

Pathways for Lung Disease

About this section

Pathways related to Lung Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Metabolism of proteins 66
Show member pathways
 13.61 ABCA3 CFTR COPA CXCL8 IFIH1 MUC5B
2
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.93 CXCL8 IL10 IL1B SFTPA2 SFTPD TNF
3
IL-17 Family Signaling Pathways 65
Show member pathways
 12.24 CFTR CXCL8 IL1B MUC5B TNF
4
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.18 CXCL8 IL10 IL1B TERT TNF
5
IL-1 Family Signaling Pathways 65
Show member pathways
 12.14 CFTR CXCL8 IL1B MUC5B TNF
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.1 CXCL8 IL10 IL1B TNF
7
Bacterial infections in CF airways 22
Show member pathways
 12.02 CFTR CXCL8 IL1B SFTPA1 SFTPD TNF
8
Interleukin-4 and 13 signaling 66
11.91 CXCL8 IL10 IL1B TNF
9
AGE-RAGE signaling pathway in diabetic complications 37
11.82 CXCL8 IL1B TNF
10
Hematopoietic cell lineage 37
11.81 IL1B ITGA3 TNF
11
Amoebiasis 37
11.81 CXCL8 IL10 IL1B TNF
12
NF-kappa B signaling pathway 37
11.8 CXCL8 IL1B TNF
13
Diseases of metabolism 66
Show member pathways
 11.77 SFTPA1 SFTPA2 SFTPB SFTPC SFTPD
14
Rheumatoid arthritis 37
11.76 CXCL8 IL1B TNF
15
Innate Lymphoid Cell Differentiation Pathways 65
11.71 IL10 IL1B TNF
16
Dendritic Cells Developmental Lineage Pathway<